Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39110
Title: | A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung) | Authors: | Schuler, M. H. H. CUPPENS, Kristof Ploenes, T. Vanbockrijck, M. Wiesweg, M. Darwiche, K. Schramm, A. MAES, Brigitte Hegedus, B. Schildhaus, H-U. Hautzel, H. Theegarten, D. Baas, P. Hartemink, K. Du Pont, B. Aigner, C. |
Issue Date: | 2022 | Publisher: | ELSEVIER | Source: | ANNALS OF ONCOLOGY, 33 (7) , p. S1404 | Abstract: | Background: Preoperative immune checkpoint inhibitor therapy (PICIT) is a promising approach in curative treatment of non-small-cell lung cancer (NSCLC). This study explores the feasibility and efficacy of targeting PD-1 and LAG-3 prior to resection. | Document URI: | http://hdl.handle.net/1942/39110 | ISSN: | 0923-7534 | e-ISSN: | 1569-8041 | DOI: | 10.1016/j.annonc.2022.08.034 | ISI #: | 000866211602444 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung).pdf Restricted Access | Published version | 85.97 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.